Capricor Therapeutics Files 8-K
Ticker: CAPR · Form: 8-K · Filed: Mar 4, 2025 · CIK: 1133869
| Field | Detail |
|---|---|
| Company | Capricor Therapeutics, Inc. (CAPR) |
| Form Type | 8-K |
| Filed Date | Mar 4, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-statements, exhibits, disclosure
Related Tickers: CAPR
TL;DR
CAPR filed an 8-K on March 4, 2025, mostly for financial statements and exhibits.
AI Summary
On March 4, 2025, Capricor Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine disclosure of financial information and corporate events. No specific material events or financial figures beyond the filing date were detailed in the provided text.
Why It Matters
This filing serves as a public record of Capricor Therapeutics' financial status and any significant corporate events, providing transparency for investors and stakeholders.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for financial statements and exhibits, not indicating any immediate material adverse events.
Key Players & Entities
- CAPRICOR THERAPEUTICS, INC. (company) — Registrant
- 0001558370-25-002097 (document_id) — Accession Number
- March 4, 2025 (date) — Report Date
- Delaware (jurisdiction) — State of Incorporation
- 001-34058 (company_id) — Commission File Number
FAQ
What is the primary purpose of this 8-K filing by Capricor Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report financial statements and exhibits, as indicated by the 'ITEM INFORMATION' section.
On what date was this 8-K report filed?
This 8-K report was filed on March 4, 2025.
What is the Commission File Number for Capricor Therapeutics, Inc.?
The Commission File Number for Capricor Therapeutics, Inc. is 001-34058.
In which state was Capricor Therapeutics, Inc. incorporated?
Capricor Therapeutics, Inc. was incorporated in Delaware.
What is the company's principal executive address mentioned in the filing?
The company's principal executive address is 10865 Road to the Cure, Suite 150, San Diego, California.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 4, 2025 regarding CAPRICOR THERAPEUTICS, INC. (CAPR).